Medicus Pharma (MDCX) EBITDA (2024 - 2026)
Medicus Pharma's (MDCX) quarterly EBITDA came in at -$7.8 million in Q4 2025, down 117.28% YoY from $45.1 million in Q4 2024, and down 51937233.33% on a QoQ basis from -$15.0 in Q3 2025.
Medicus Pharma (MDCX) EBITDA (2024 - 2026) Analysis & Trends
Medicus Pharma (MDCX) has 2 years of EBITDA data on file, last reported at -$7.8 million in Q4 2025.
- Quarterly EBITDA fell 117.28% year-over-year to -$7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$18.9 million (down 69.33% YoY) and the FY2025 annual result came in at -$34.4 million, down 207.3% from the prior year.
- EBITDA fell to -$7.8 million in Q4 2025, from -$15.0 in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$15.0 in Q3 2025 to a low of -$7.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Medicus Pharma | 14.88 Mn | -298,205.43 | - | -11.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.48 Mn |
| Dec 31, 2025 | -7.79 Mn |
| Sep 30, 2025 | -15.00 |
| Jun 30, 2025 | -6.02 Mn |
| Mar 31, 2025 | -5.13 Mn |
| Dec 31, 2024 | -3.59 Mn |
| Sep 30, 2024 | -2.33 Mn |
| Jun 30, 2024 | -3.55 Mn |
| Mar 31, 2024 | -1.71 Mn |